Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Ruxolitinib for Patients With Primary Myelofibrosis

July 13th 2021

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

Monitoring Disease Response or Progression in MF

July 6th 2021

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Recent Updates to NCCN Guidelines on MF Treatment

July 6th 2021

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Phase 3 MOMENTUM Study Completes Enrollment in Myelofibrosis

July 1st 2021

Enrollment to the pivotal phase 3 MOMENTUM trial, which is evaluating the novel JAK1/2 and ACVR1/ALK2 inhibitor momelotinib vs danazol in patients with symptomatic myelofibrosis and anemia, has completed.

Using NGS to Inform More Than Diagnosis in Myeloid Malignancies

June 29th 2021

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

Therapeutic Decision-Making for Primary Myelofibrosis

June 29th 2021

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

Diagnosis and Prognosis of Primary Myelofibrosis

June 29th 2021

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

Dr. Mesa on the Unique Characteristics of Pacritinib in Myelofibrosis

June 24th 2021

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Dr. Kiladjian on the Potential Utility of Momelotinib in Myelofibrosis

June 21st 2021

Jean-Jacques Kiladjian, MD, PhD, discusses, the potential utility of momelotinib in myelofibrosis.

Transfusion Independence With Momelotinib Confers Benefit Regardless of Baseline Factors in Myelofibrosis

June 18th 2021

Achieving transfusion independence after 24 weeks of treatment with momelotinib is associated with clinical benefit in patients with myelofibrosis irrespective of the degree of anemia, platelet count, or transfusion status at baseline.

Dr. Mascarenhas on Potential for Pacritinib to Address an Unmet Need in Myelofibrosis

June 17th 2021

John O. Mascarenhas, MD, discusses the potential for pacritinib to address an unmet need in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Efficacy of Pacritinib in Myelofibrosis

June 17th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.

Symptom Improvement Appears Similar With Momelotinib Vs Ruxolitinib in Myelofibrosis

June 17th 2021

Momelotinib can provide clinically relevant and comparable improvement in overall symptom burden and individual symptom items compared with ruxolitinib in patients with intermediate- and high-risk JAK inhibitor–naïve myelofibrosis.

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

June 16th 2021

The FDA has approved avapritinib (Ayvakit) for the treatment of adult patients with advanced systemic mastocytosis, including those with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

Improvements in Cardiovascular Risk Management Needed for MPN

June 11th 2021

Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.

Dr. Mesa on Data With Momelotinib in Transfusion Independence Responders in Myelofibrosis

June 11th 2021

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis

June 10th 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

June 10th 2021

Jan Philipp Bewersdorf, MD, discusses the role of allogeneic hematopoietic cell transplant in myelofibrosis.

Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis

June 10th 2021

Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.

Novel Combination Holds Potential to Address All Hallmarks of Myelofibrosis

June 10th 2021

In an effort to build on the efficacy demonstrated with ruxolitinib, investigators are evaluating combination therapies—specifically the dual inhibition of the JAK-STAT and BET pathways using pelabresib, a novel BET inhibitor.